Residency · Residency · Pathology

Normal Hematopoiesis and Bone Marrow Evaluation

Overview

Bone marrow evaluation is a cornerstone of hematopathology, essential for diagnosing hematologic malignancies, cytopenias, and systemic diseases affecting the marrow. A systematic approach integrating core biopsy histology, aspirate smear morphology, flow cytometry, cytogenetics, and molecular studies is required for accurate diagnosis and classification according to current WHO and ICC systems.

Normal Hematopoiesis

Hematopoietic Hierarchy

All blood cells derive from a single self-renewing, multipotent hematopoietic stem cell (HSC) residing in the bone marrow niche. The HSC gives rise to multipotent progenitors (MPPs), which differentiate into either a common myeloid progenitor (CMP) or a common lymphoid progenitor (CLP). The CMP gives rise to the erythroid, megakaryocytic, granulocytic (neutrophil, eosinophil, basophil), and monocytic lineages. The CLP produces B-cells, T-cells, and NK cells. This process is regulated by hematopoietic growth factors: erythropoietin (EPO) drives erythropoiesis, G-CSF promotes granulopoiesis, thrombopoietin (TPO) stimulates megakaryopoiesis, and M-CSF promotes monocyte production.

Normal Maturation Sequences

Granulocytic (Neutrophilic) Series

The granulocytic maturation sequence proceeds from myeloblast through promyelocyte, myelocyte, metamyelocyte, and band forms to the segmented neutrophil. As cells mature, they become progressively smaller, their nuclei condense, nucleoli disappear, and cytoplasmic granules appear -- primary (azurophilic) granules at the promyelocyte stage and secondary (specific) granules at the myelocyte stage. The normal myeloid-to-erythroid (M:E) ratio ranges from 2:1 to 4:1.

Erythroid Series

Erythroid maturation follows the sequence from pronormoblast through basophilic, polychromatic, and orthochromatic normoblasts to the reticulocyte and finally the mature red blood cell. Progressive maturation is marked by decreasing cell size, nuclear condensation with eventual extrusion of the pyknotic nucleus, and increasing cytoplasmic eosinophilia as hemoglobin accumulates.

Megakaryocytic Series

Megakaryocyte development proceeds from megakaryoblast through promegakaryocyte and granular megakaryocyte to the mature platelet-shedding megakaryocyte. A unique feature is endomitosis, which produces polyploid nuclei ranging from 8N to 64N without cell division. Normal megakaryocytes are scattered (not clustered), appear at roughly 5-10 per low-power field, and have multilobated nuclei.

Monocytic Series

The monocytic lineage proceeds from monoblast through promonocyte to circulating monocyte. These cells are often morphologically difficult to distinguish from immature granulocytic forms, and esterase stains and flow cytometry aid identification.

Bone Marrow Biopsy: Procedure and Processing

Specimen Components

A complete bone marrow evaluation requires multiple specimen components. The core biopsy is a 1.5-2 cm trephine biopsy from the posterior iliac crest that provides architectural information. The aspirate is liquid marrow used for smear preparation, flow cytometry, cytogenetics, and molecular studies. Touch preparations (imprints) are made by touching the core biopsy surface to glass slides and are invaluable when the aspirate is hemodilute or yields a dry tap. The clot section is aspirate clot processed as FFPE tissue, providing supplementary histologic material.

Processing

The core biopsy is fixed in formalin (or B5/zinc formalin for superior nuclear detail), decalcified, embedded in paraffin, and routinely stained with H&E and reticulin. The aspirate is prepared as Wright-Giemsa stained smears with a 500-cell differential count performed on adequately cellular areas. Touch preparations receive Wright-Giemsa or Diff-Quik staining.

Adequacy Assessment

A minimum core biopsy length of 1.5 cm is recommended, containing subcortical marrow with intact architecture. An adequate aspirate contains visible spicules with intact cellular trails; hemodilute specimens may significantly underestimate cellularity and blast percentage. A dry tap -- the failure to aspirate marrow -- occurs in fibrosis, densely packed marrow (as in leukemia), or extensive metastatic disease. In this situation, touch preparations become essential for morphologic assessment.

Systematic Bone Marrow Evaluation

Step 1: Cellularity Assessment

Cellularity is defined as the percentage of marrow space occupied by hematopoietic cells versus fat. Normal cellularity is age-adjusted: infants and children show 80-100% cellularity, young adults approximately 60-70%, middle-aged adults 40-60%, and elderly individuals over 70 years may show only 20-40%. A rough rule of thumb is that cellularity approximately equals 100 minus the patient's age, though considerable individual variability exists. Hypercellularity suggests leukemia, myeloproliferative neoplasm, or reactive states. Hypocellularity suggests aplastic anemia, hypoplastic myelodysplastic syndrome, or post-chemotherapy marrow recovery.

Step 2: Trilineage Maturation

Each hematopoietic lineage is assessed for orderly maturation, appropriate proportion, and the presence of dysplastic features. In the erythroid series, the pathologist looks for normoblastic maturation and any evidence of megaloblastic change or dysplastic features such as nuclear budding, karyorrhexis, internuclear bridging, or ringed sideroblasts. In the granulocytic series, progressive maturation from blasts to segmented forms should be orderly; concerning features include hypogranularity, pseudo-Pelger-Huet anomaly (bilobed neutrophils), and abnormal localization of immature precursors (ALIP). Megakaryocyte assessment evaluates number, size, nuclear lobation, and clustering patterns. Hypolobated or monolobated megakaryocytes suggest MDS, hyperlobated megakaryocytes suggest MPN, and clustering is characteristic of myeloproliferative neoplasms.

Step 3: Blast Enumeration

Blast percentage is counted on the aspirate smear using a 500-cell differential, which serves as the gold standard. The core biopsy provides an estimate or uses immunohistochemistry for CD34 and CD117 for confirmation. Normal marrow contains fewer than 5% blasts. AML is defined at 20% or greater blasts, with exceptions in the WHO 5th edition for AML with certain defining genetic abnormalities (which can be diagnosed at 10% or greater). MDS is diagnosed when blasts are below 20% but dysplasia and/or cytogenetic abnormalities are present.

Step 4: Iron Assessment

Prussian blue (Perls) staining on aspirate or clot sections evaluates iron status. Storage iron (macrophage hemosiderin) is graded from 0 (absent) to 6+ (excessive). Ringed sideroblasts are erythroid precursors with 5 or more iron granules encircling at least one-third of the nuclear circumference; 15% or more ringed sideroblasts defines MDS with ring sideroblasts (or 5% or more if an SF3B1 mutation is present). Iron deficiency shows absent storage iron and absent sideroblasts. Iron overload, whether from transfusion or hemochromatosis, shows markedly increased storage iron.

Step 5: Reticulin and Fibrosis Assessment

Reticulin staining on the core biopsy grades marrow fibrosis according to the WHO/European Consensus system. MF-0 represents normal scattered reticulin fibers without intersections. MF-1 shows a loose network of reticulin with some intersections. MF-2 demonstrates a diffuse dense increase in reticulin with extensive intersections and focal collagen bundles visible on trichrome stain. MF-3 shows diffuse dense reticulin with coarse collagen bundles (trichrome-positive) and often osteosclerosis. MF-2 and MF-3 fibrosis occurs in primary myelofibrosis, post-polycythemia vera and post-essential thrombocythemia myelofibrosis, hairy cell leukemia, metastatic disease, and autoimmune myelofibrosis.

Step 6: Ancillary Studies

Flow Cytometry

Flow cytometry is essential for blast immunophenotyping, determining lineage assignment, and identifying aberrant marker expression. It detects minimal residual disease (MRD) at 0.01% sensitivity. Standard panels include CD45 gating with myeloid markers (CD13, CD33, CD117, MPO), B-lymphoid markers (CD19, CD10, CD20, CD22), T-lymphoid markers (CD3, CD4, CD8, CD7, CD5), monocytic markers (CD14, CD64), and erythroid markers (CD71, glycophorin A). Aberrant expression patterns define leukemia-associated immunophenotypes (LAIPs) used for subsequent MRD monitoring.

Cytogenetics

Conventional karyotyping analyzes 20 metaphases to identify translocations, deletions, and chromosomal gains. It is essential for risk stratification in AML, MDS, and ALL. Key examples include t(8;21), inv(16), and t(15;17) in AML, and del(5q), del(7q), and complex karyotype in MDS.

Molecular Studies

Next-generation sequencing panels test for mutations in genes including FLT3, NPM1, CEBPA, IDH1/2, DNMT3A, TET2, ASXL1, TP53, RUNX1, SF3B1, and SRSF2. RT-PCR detects specific fusion transcripts such as BCR-ABL1 in CML and PML-RARA in APL. FISH provides targeted detection of specific abnormalities when the karyotype is normal or non-informative.

<image>A medical illustration showing normal bone marrow histology and aspirate morphology. Panel A: Low-power core biopsy (H&E) from a 30-year-old adult showing approximately 50% cellularity with interstitial fat interspersed between hematopoietic elements, including recognizable erythroid islands, granulocytic precursors, and scattered megakaryocytes. Panel B: High-power aspirate smear (Wright-Giemsa) showing orderly trilineage hematopoiesis with labeled examples of each maturation stage -- myeloblast, promyelocyte, myelocyte, metamyelocyte, band, segmented neutrophil in the granulocytic series, and pronormoblast through orthochromatic normoblast in the erythroid series, with a mature megakaryocyte with multilobated nucleus in the background.</image>

<image>A medical illustration demonstrating the reticulin fibrosis grading system (MF-0 through MF-3) on bone marrow core biopsy sections. Panel A (MF-0): Scattered fine reticulin fibers without intersections on reticulin stain. Panel B (MF-1): Loose network of reticulin with some intersections, particularly perivascular. Panel C (MF-2): Dense diffuse increase in reticulin with extensive intersections, with an inset trichrome stain showing focal collagen (blue) bundles. Panel D (MF-3): Coarse dense reticulin network with osteosclerosis, paired with a trichrome stain showing extensive collagen deposition (blue bands) replacing hematopoietic marrow.</image>

<image>A medical illustration showing the Prussian blue iron stain assessment on bone marrow aspirate. Panel A: Normal iron stores with blue granules within macrophages (storage iron, grade 2-3+) and scattered sideroblasts (erythroid precursors with 1-4 fine blue cytoplasmic granules). Panel B: Iron deficiency with completely absent macrophage hemosiderin and no sideroblasts. Panel C: Iron overload with abundant coarse blue granules filling macrophages (grade 5-6+). Panel D: Ring sideroblasts at high magnification showing erythroid precursors with five or more iron granules arranged in a ring encircling at least one-third of the nuclear circumference, with an arrow highlighting the perinuclear ring pattern characteristic of MDS with ring sideroblasts.</image>

Clinical Pearls

Always compare aspirate blast counts with core biopsy immunohistochemistry for CD34 and CD117, as a hemodilute aspirate may undercount blasts while a packed marrow may not aspirate at all. The aspirate remains the gold standard for blast enumeration; however, in a dry tap, the touch preparation differential or core biopsy IHC estimation must be used. Ringed sideroblasts must be counted on aspirate Prussian blue iron stain because core biopsy iron staining is unreliable for sideroblast assessment. Age-adjusted cellularity assessment is critical: a 30% cellular marrow is hypocellular for a 20-year-old but entirely normal for a 70-year-old. Megakaryocyte morphology is a powerful diagnostic clue: hypolobated forms suggest MDS, clustered hyperlobated megakaryocytes with bulbous nuclei suggest essential thrombocythemia, clustered megakaryocytes with cloud-like nuclei suggest primary myelofibrosis, and small hypolobated megakaryocytes suggest 5q-deletion MDS. Flow cytometry aberrancies in blasts (such as CD7 on myeloid blasts, dim CD45, or asynchronous maturation) define leukemia-associated immunophenotypes used for MRD monitoring. CHIP (clonal hematopoiesis of indeterminate potential) mutations including DNMT3A, TET2, and ASXL1 are found in more than 10% of healthy individuals over age 70, and their detection on NGS does not constitute a myeloid neoplasm without correlating morphology and clinical findings.

References

• Swerdlow SH, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th ed. IARC; 2017.
• Khoury JD, et al. The 5th edition of the WHO Classification of Haematolymphoid Tumours. Leukemia. 2022;36(7):1703-1719.
• Arber DA, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias. Blood. 2022;140(11):1200-1228.
• Bain BJ, Clark DM, Wilkins BS. Bone Marrow Pathology. 5th ed. Wiley-Blackwell; 2019.
• Thiele J, et al. European consensus on grading bone marrow fibrosis. Haematologica. 2005;90(8):1128-1132.

Read this lecture as Markdown